

Amendments to the Claims:

Please amend claims 1 and 8 as follows, and please cancel claim 7 without prejudice to continued prosecution. The claims and their status are shown below. This listing of claims replaces all prior versions and listings of claims in the application.

1. (Currently amended) An isolated antisense oligonucleotide consisting essentially of ~~40 to 50~~ 12 to 40 nucleotides, wherein said oligonucleotide specifically hybridizes within an accessible region of TRPC4 mRNA, said region defined by nucleotides 43 through 86 of SEQ ID NO:1, and wherein said oligonucleotide inhibits the production of TRPC4.

2. (Original) A composition comprising the isolated antisense oligonucleotide of claim 1.

3. (Canceled)

4. (Previously Presented) A nucleic acid construct comprising a regulatory element operably linked to a nucleic acid encoding a transcript, wherein said transcript consists essentially of 10 to 50 nucleotides and specifically hybridizes within an accessible region of TRPC4 mRNA in its native form, wherein said accessible region is defined by nucleotides 43 through 86 of SEQ ID NO:1.

5. (Original) A host cell comprising the nucleic acid construct of claim 4.

6. (Withdrawn—Previously Presented) A method of decreasing production of TRPC4 in cells or tissues, comprising contacting said cells or tissues with the isolated antisense oligonucleotide of claim 1.

7. (Cancelled)

8. (Withdrawn—Currently Amended) A method for modulating pain in a mammal, said method comprising administering the isolated antisense oligonucleotide of claim [[7]] 1 to said mammal.

9-15. (Canceled)